Executive Vice President, Research and Investments & Chief Scientific Officer · Royalty Pharma plc (RPRX)

James Reddoch

A named executive officer of Royalty Pharma in every fiscal year CompBrief holds from FY2019 to FY2020. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$3,395,000

Salary $895,000Stock awards $0Bonus $2,500,000

FY2019: $2,082,500

5th of 5 named executive officers at Royalty Pharma by FY2020 total.

5 named officers on file for Royalty Pharma, FY2020

James Reddoch’s pay file — $29

  • 2 fiscal years of pay, line by line
  • RPRX’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Royalty Pharma’s whole pay program stands against its peers

  • Royalty Pharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RPRX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2021 (DEF 14A).

Free

Get James Reddoch’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

James Reddoch compensation by year

Royalty Pharma Summary Compensation Table · all 2 fiscal years held
In US dollars, as Royalty Pharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020
Salary$682,500$895,000
Bonus$1,400,000$2,500,000
Stock awards$0$0
Option awards$0$0
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$0$0
Total$2,082,500$3,395,000

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Royalty Pharma plc DEF 14A filed April 29, 2021, accession 0001140361-21-014879, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Royalty Pharma plc filed document, accession 0001140361-21-014879. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2021.

$2.1M
$3.4M
FY19
FY20
SalaryBonus

Royalty Pharma’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Pablo LegorretaChief Executive Officer$55,674,558
Christopher HiteExecutive Vice President & Vice Chairman$3,644,711
Terrance CoyneExecutive Vice President & Chief Financial Officer$3,395,000
George LloydExecutive Vice President, Investments & General Counsel$3,395,000
James Reddoch · this pageExecutive Vice President, Research and Investments & Chief Scientific Officer$3,395,000

The full Royalty Pharma compensation record

free company brief

This page is one person within Royalty Pharma's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Royalty Pharma proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Royalty Pharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

James Reddoch's compensation dossier · One-time report. No refunds.